Navigation Links
Using fMRI to study brain development
Date:11/30/2007

Functional magnetic resonance imaging (fMRI) is a powerful noninvasive tool for studying brain activity in both humans and experimental animals. Most fMRI studies are carried out on adults, but this technique also has great potential for studying early brain development. That potential is hampered, however, by a lack of knowledge about the basis of the fMRI signal in the developing brain. Now, by studying rats, MIT neuroscientists show that the fMRI signal changes during first few weeks of life. By correcting for those changes, the researchers were able to monitor the development of the rat brain. Determining whether analogous changes occur in humans will be important for interpreting developmental fMRI studies in young children.

Our study lays a foundation for using fMRI to study development, explains senior author Alan Jasanoff, Associate Member of the McGovern Institute and Assistant Professor of Nuclear Science and Engineering . It establishes an approach that others can apply to investigate many aspects of neurodevelopment in very young animals. Jasanoff collaborated with the lab of developmental biologist Martha Constantine-Paton, a McGovern Institute Principal Investigator. The study was published online November 25, in the journal Nature Neuroscience.

A fundamental difficulty in interpreting fMRI is that it provides only an indirect readout of brain activity, based on changes in the brains blood supply. Increases in brain activity cause increased blood flow, but the coupling mechanism that links these two processes is itself subject to change in early life. Thus, a weak fMRI signal in young animals could mean less neural activity, or it could simply mean that MRI cannot detect that activity because of weak neurovascular coupling.

To resolve this uncertainty, Jasanoff and colleagues compared fMRI signals with direct electrical recordings of neuronal activity as they stimulated rats forepaws. In animals younger than 11 days, they could not detect fMRI signals, even though electrical recordings showed that the brain was responding to stimulation. The fMRI signals became both stronger and faster as the animals matured, until they approached adult levels by about 3 weeks of age. This corresponds approximately to 7-8 years in terms of human brain development.

By compensating for these age-related changes, the authors were able to track the development of connections between different touch-sensitive brain regions as the animals matured.

The researchers also investigated what molecular events might underlie the changing relationship between neural activity and the blood response. Their findings suggest that a key player is carbonic anhydrase (CA), a well-known enzyme that helps remove carbon dioxide from the blood. Age-related increases in CA activity corresponded to the changes in the fMRI signal, and drugs that block the activity of this enzyme in adult animals caused the fMRI signal to regress to that seen in younger animals. CA is an important target for drugs used to treat diverse conditions, including glaucoma, altitude sickness and epilepsy, so it will be interesting to determine whether such drugs alter the relationship between activity and blood flow in the adult human brain.

In the longer term, Jasanoff hopes to circumvent the difficulties of fMRI altogether, by developing new methods that will make it possible to visualize neural activity directly, rather than indirectly through its effect on blood flow.


'/>"/>

Contact: Charles Jennings
charlesj@mit.edu
617-324-3977
McGovern Institute for Brain Research
Source:Eurekalert

Related biology news :

1. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
2. Fever causing headaches for Aussie parents
3. Using evolution, UW team creates a template for many new therapeutic agents
4. Using green chemistry to deliver cutting-edge drugs
5. IGERT fellows to design biodevices using flexible electronics
6. Prediction of RNA pseudoknots using heuristic modeling with mapping and sequential folding
7. Computer program traces ancestry using anonymous DNA samples
8. Using nanotubes to detect and repair cracks in aircraft wings, other structures
9. Book on weeds and invasive plants discusses how to manage them using ecological approaches
10. Study shows housing development on the rise near national forests
11. Rare cancer-causing syndrome found, for the first time, in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... WASHINGTON , Feb. 3, 2017 A ... Identity Strategy Partners, LLP (IdSP) . Designed to ... in the complex identity market, founding partners Mark ... nearly 35 combined years just in identity expertise that ... tank and non-profit leadership. The Crego-Kephart combined expertise has ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/30/2017)... 2017   Invitae Corporation (NYSE: ... companies, today announced that it will report its fourth ... guidance on Monday, February 13, 2017, and Invitae,s management ... 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... review financial results, guidance, and recent developments and will ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... According to a new ... Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, ... Development, Disease-Risk) - Global Forecast to 2021" published ... USD 53.34 Billion by 2021 from USD 27.95 ... 13.8% during the forecast period (2016-2021). ...
(Date:2/17/2017)... Feb. 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... its oral peptide drug candidates, PTG-100 and PTG-200, ... European Crohn,s and Colitis Organization (ECCO).  The ECCO ... Spain from February 15 – 18, ... data on Protagonist drug candidates PTG-100 and PTG-200. ...
(Date:2/16/2017)... Calif. and GREENWICH, Conn. ... a private investment firm focused on venture growth ... the promotion of Josh Richardson , M.D. ... on investments in biotechnology companies.  He is a ... played important roles in Longitude,s investments in Aimmune ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
Breaking Biology Technology: